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A B S T R A C T
We have evaluated a miniaturized in vitromethod, based on themDISS ProﬁlerTM technique that enables
on-line monitoring of drug release from a 21ml sample with 10ml of release medium. Four model drugs
in eight clinically used formulations, including both solid and non-solid drug delivery systems, were
investigated. The acquired data were compared with historical in vitro release data from the same
formulations. Use of the Weibull function to describe the in vitro drug-release proﬁles allowed
discrimination between the selected formulations with respect to the drug-release mechanisms.
Comparison of the release data from the same formulation in different in vitro set-ups showed that the
methodology used can affect themechanism of in vitro release.We also evaluated the ability of the in vitro
methods to predict in vivo activity by comparing simulated plasma concentration-time proﬁles acquired
from the application of the biopharmaceutical software GI-Sim to the in vitro observations. In summary,
the simulations based on the miniaturized-method release data predicted the plasma proﬁles as well as
or more accurately than simulations based on the historical release data in 71% of the cases and this
miniaturized in vitro method appears to be applicable for both solid and non-solid formulations.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/
1. Introduction
Successful drug development processes beneﬁt from the
combination of in vitro methods and in silico simulations that
can predict the in vivo response (Lennernäs et al., 2014a). To enable
accurate in vivo predictions from in vitro drug-release data, the
drug must be released from the formulation by a similar
mechanism both in vivo and in vitro (Larsen et al., 2013). There
are standardized in vitro quality control release methods for oral
formulations, as described for example in the US Pharmacopeia
(USP). The USP experimental set-ups include the paddle, rotation
and reciprocating cylinder apparatuses. However, these methods
might not always be accurately predictive of the in vivo situation
(Kostewicz et al., 2014b). Adjustments to the stirring rate,
temperature and release medium (surfactant, ionic strength and
pH) could alter the release rates to varying degrees, and
information on this would be of value for accelerated and
biorelevant in vitro release studies of modiﬁed-release formula-
tions (Shen and Burgess, 2012). The use of a biorelevant medium
that mimics the dynamic gastrointestinal ﬂuid has also been
shown to increase the predictability of in vitro methods (Klein,
2010; Kostewicz et al., 2014b).
The mDISS proﬁlerTM, a miniaturized dissolution apparatus that
uses only small amounts of active pharmaceutical ingredient (API)
andreleasemedium,wasdeveloped tomeasurethesolubilityofAPIs
in early drug development (Fagerberg et al., 2010; Tsinman et al.,
2009). Importantly, this apparatus continuously monitors absor-
bance,usingaﬁber-opticUVdipprobe locatedcentrally inaglassvial
(Avdeef and Tsinman, 2008). The mini-IDRTM disc, an additional
application for the mDISS proﬁlerTM, enables measurement of the
intrinsicdissolutionrate (IDR).Because theexposedareaof theAPI is
constant when measuring the IDR, it has been used to characterize
dissolution proﬁles (Avdeef and Tsinman, 2008).
Theoretical modeling is a useful tool in pharmaceutical
development; it is used to investigate and characterize the release
of the API from the drug delivery system (DDS) and to determine
which factors inﬂuence the release rate (Siepmann and Siepmann,
2012). This type of knowledge is also useful during the innovation
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and development of novel DDSs where a speciﬁcally designed
drug-release proﬁle is needed to target speciﬁc pharmacodynamic
and safety properties (Johannsson et al., 2011; Selen et al., 2014;
Siepmann and Siepmann, 2012; Sjögren et al., 2014).
The primary objective of this study was to improve under-
standing of the novel,miniaturized, in vitro,mDISSTM-based release
method and to examine its potential for predicting in vivo data. The
in vivo predictive abilities of release data from this novel method
and of historical in vitro release data were compared using in silico
simulations and themechanisms of API release from selected DDSs
were investigated using the Weibull function.
2. Materials and methods
2.1. Chemicals and drug delivery systems
Four APIs (metoprolol, diclofenac, naproxen and carbamaze-
pine (Sigma–Aldrich, Sweden)), representing biopharmaceutics
classiﬁcation system (BCS) classes I and II (Wu and Benet, 2005),
were investigated. Their physicochemical properties are listed in
Table 1. The chosen drugs have typical physicochemical properties
for drugs that are formulated inmodiﬁed release dosage forms. The
lipophilicity (log P) covers a three-fold range but the molecular
weight covered a narrow range. Stock solutions were prepared by
dissolving each API in ethanol (Solveco, Sweden). Mono- and
dibasic potassium phosphate, used to prepare phosphate buffer
saline (PBS), was acquired from Riedel de Haën, Germany.
The in vitro release proﬁles of eight clinically used DDSs were
investigated. Two of the DDSswere non-solid formulations (an oral
suspension and a gel for dermal application), two were oral
modiﬁed-release (MR) tablets, and four were oral immediate-
release (IR) tablets. The IR tablets contained metoprolol tartrate
(SelokenTM 50mg, Astra Zeneca, Sweden), naproxen (PronaxenTM
250mg, Orion Pharma, Sweden), carbamazepine (TegretolTM
100mg, Novartis, Sweden), and diclofenac (VoltarenTTM 25mg,
Novartis, Sweden). The MR tablets contained metoprolol succinate
(Seloken ZOCTM 25mg, Astra Zeneca, Sweden), and carbamazepine
(Tegretol RetardTM 200mg, Novartis, Sweden). The non-solid DDSs
were a diclofenac dermal gel (VoltarenTM gel 11.6mg/g), and an
oral suspension of carbamazepine (TegretolTM oral suspension
20mg/ml), both from Novartis, Sweden.
2.2. Sample reservoirs for themodiﬁedmDISSTM-based release method
The dimensions of the mini-IDRTM disc were used as a starting
point for developing a sample reservoir made of magnetic ferritic
stainless steel, an Fe–Cr alloy (Olsson and Landolt, 2003). A small
cylindrical cavity, 3mm deep and 3mm in diameter, with a sample
volume of 21ml, was drilled centrally in the steel disc (Fig. 1). The
opening was covered with a diffusion barrier (see description
below) to retain the formulation sample in the reservoir. The
diffusion barrier was held in place with a ring-shaped magnet
placed centrally over the reservoir opening (Fig. 1).
2.3. Experimental design
A mDiss proﬁlerTM (pION, USA) was used for all of the
miniaturized in vitro release experiments (Fig.1). The UV dip probe
in the mDiss proﬁlerTM automatically performs spectral scans at
intervals of 200–720nm and calculates the drug concentration as
the area under the concentration-time curve (AUC) of the second
derivate spectrum. The second derivate spectrum enhances the
peaks and reduces baseline shifting of the UV spectrum, which
reduces the effects of background turbidity (Avdeef et al., 2009;
Bijlani et al., 2007). The drug release studies were performed in
triplicate; for each experiment, a 21ml samplewas inserted into the
sample reservoir and 10ml of PBS buffer, pH 7.4,was added. A pH of
7.4was chosenmainly because themethod is intended for usewith
drugs delivered parenterally. However, it should be noted that the
average ionizationof theAPIsat thispHwasnodifferent fromthatat
the intestinal pH of 6.8. If not otherwise stated, the stirring ratewas
set at 400 rpm. A nylon mesh ﬁlter (pore size 150mm), a
polyvinylidene ﬂuoride ﬁlter (pore size 0.45mm) and a cellulose-
based dialysis membrane (approximate pore size 0.003mm) were
usedasdrugdiffusionbarriers.Thesediffusionbarrierswere soaked
in de-ionized water for 10min at room temperature before use.
During the drug release experiments, the temperature was kept at
37 C using a water bath (Lauda, Germany).
2.4. In vitro release studies
In the miniaturized method, in vitro studies investigated the
effect of the choice of diffusion barrier on the time taken for
metoprolol and diclofenac (dissolved in de-ionized water) to reach
equilibrium, and the effect of the stirring rate (100–400 rpm) on
the mass transport of metoprolol and diclofenac across the
diffusion barrier. The polyvinylidene ﬂuoride ﬁlter (pore size
0.45mm) provided appropriate mass transport values for these
APIs and was use as the diffusion barrier in the stirring-rate
hydrodynamic experiments.
All the solid formulations except metoprolol MR were crushed
and sieved (Retsch, Germany) to prepare the material for the
Table 1
Physicochemical properties of the active pharmaceutical ingredients (APIs)
included in the study.
API Mw S0 pKa log P BCS class
Metoprolol 267.37a 200f700g,e 9.7 (base)b 1.88a I
Diclofenac 296.16a 0.375a 3.8 (acid)c 4.51a II
Naproxen 230.27a 0.115a 4.4 (acid)b 3.18a II
Carbamazepine 236.28a 0.256a 14 (base)d 2.45a II
BCS: biopharmaceutical classiﬁcation system; log P: logarithm of the partitioning
coefﬁcient; Mw: molecular weight; pKa: acid dissociation constant; S0: solubility
(mg/ml).
a Benet et al. (2011).
b Fagerholm et al. (1997).
c O’Connor and Corrigan (2001).
d Scheytt et al. (2005).
e Ragnarsson et al. (1987).
f Metoprolol succinate.
g Metoprolol tartrate.
[(Fig._1)TD$FIG]
Fig. 1. A schematic illustration of the principles of the novel miniaturized in vitro
release method. (1) The formulation sample is inserted into the sample reservoir.
(2) The diffusion barrier ismounted and the ring-shapedmagnet is attached to keep
the diffusion barrier and the formulation sample in place. (3) The sample reservoir
is placed in the glass vial and the release medium is added. The drug release is
measured continuously with the mDISSTM UV-dip probe.
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sample reservoir. The fraction of particles sized between 0.7 and
1.0mmwas collected and used for the in vitro release experiments.
Thematrix of themetoprololMR tabletwas dissolved in de-ionized
water immediately prior to the experiment; within 5min it
disintegrated into small ethylcellulose-coated pellets (approxi-
mate size 0.5mm) (Ragnarsson et al., 1987). Just before the start of
the experiment, either the crushed particle fraction or the coated
pellets were mixed with de-ionized water to create a slurry. 21ml
of the resulting slurry was inserted into the sample reservoir and
coveredwith the diffusion barrier, in this case the nylonmesh ﬁlter
(pore size 150mm). The slurry was used to avoid air being trapped
in the sample cavity and beneath the diffusion barrier, which could
have reduced the mass transport of the API across the diffusion
barrier. The non-solid DDSs (the gel and oral suspension) were
inserted directly into the sample reservoir. All experiments were
performed in triplicate.
Historical in vitro and in vivo data on the eight DDSs were
collected from published reports (Al Ameri et al., 2012; Elqidra
et al., 2004; Friedman et al., 2000; Gohel et al., 2009; Kovacevic
et al., 2008; Löbenberg et al., 2005; Nan et al., 2012; Nishihata,
1987; Parsaee et al., 2002; Reiner et al., 2001; Sandberg et al., 1988;
Yuksel et al., 2000; Zhang et al., 2011; Zhou et al., 1998) and
obtained quantitatively with PlotDigitizer (Free Software Founda-
tion Inc., MA, USA).
2.5. Data analysis
The nonlinear semi-log line of the software GraphPad Prism
6.04 (GraphPad Software, Inc., USA) was used to analyze the
correlations between the pore size of the diffusion barrier and the
time to equilibrium.
Many models are available for theoretically modeling drug-
releasemechanisms (Siepmann and Siepmann, 2008). However, the
entire in vitro drug-release proﬁle can be described by the Weibull
function. In Eq. (1), theWeibull function has been slightlymodiﬁed
R%t ¼ R%max  ð1 expatb Þ (1)
R%t and R%max are the percentage of drug released at time t and the
maximum percentage released, respectively; a and b are constants
describing the drug-release proﬁle, and t is the time (Papadopou-
lou et al., 2006). The Weibull function has been reported to be
useful in comparing release proﬁles for the delivery of drugs from
various matrices (Dash et al., 2010). The combination of Monte
Carlo simulations and experimental release data has shown that
the values of b in theWeibull function can provide an indication of
the release mechanisms involved in the drug release (Papado-
poulou et al., 2006).
In this study, Eq. (1) was ﬁtted to the observed data using the
average value of each time point for both the experimental and the
historical data. The curve ﬁtting was performed using the
nonlinear least square regression in Phoenix 64 WinNonlin 6.3
software (Pharsight, USA). Estimated a and b valueswere then used
to extrapolate the release proﬁles for complete drug release. The
goodness of ﬁt for each analysis was expressed as the absolute
average fold error (AAFE), as described by Graham et al. (2012).
Absoluteaveragefolderror ¼ 10Sjlog
Predicted
Observedj
N
(2)
AAFE describes the geometric mean ratio of the predicted and
observed values and N describes the number of observations. An
AAFE value of 1 indicates a perfect ﬁt while a value of 2 indicates an
average 2-fold difference from observed data points.
2.6. In silico simulations of in vivo response
In silico simulations based on the experimental and historical in
vitro data were obtained using the gastrointestinal (GI) absorption
model GI-Sim (Sjögren et al., 2013). Brieﬂy, the GI-Sim simulates
human GI physiology with nine simulated GI compartments. The
GI compartments are connected in series to represent the stomach
(compartment 1), the small intestine (compartments 2–7) and the
colon (compartments 8–9) (Yu and Amidon, 1999; Yu et al., 1996).
Physiological parameters describing these GI compartments have
been previously reported (Sjögren et al., 2013). The GI model is
linked to a simulated systemic pharmacokinetic model, with up to
three compartments, to enable simulations and predictions of the
plasma concentration–time proﬁles. In GI-Sim drug particles and
monomers ﬂow from one GI compartment into the next. The
particles either dissolve or grow, and the monomers partition into
colloidal structures or are absorbed across the intestinal wall. The
pH-dependent solubility of an ionizable compound in the lumen is
calculated in GI-Sim according to the Henderson–Hasselbalch
equation and the physiological pH of each GI compartment
(Hasselbalch, 1916). The dissolution rate in GI-Sim is usually
described by Fick’s law and the Nielsen stirring model (Nielsen,
1961); however, in this study, the in vitro experimental release
proﬁles of the formulations were used for the appearance rate of
free monomer in the GI compartments. The effective intestinal
permeability for each API was used to describe the total serial
transport process across the aqueous boundary layer adjacent to
the intestinal wall and the small intestine membrane (Lennernäs
et al., 1996; Sandberg et al., 1991; Sjögren et al., 2013; Tubic-
Grozdanis et al., 2008). Absorption occurs in all intestinal
compartments including the colon (there is no absorption in the
stomach). The relevant physicochemical, biopharmaceutical, and
pharmacokinetic properties of the investigated APIs and formu-
lations are summarized in Table 2. The AAFE was used to analyze
Table 2
Pharmacokinetic parameters used in in vivo simulations.
API CL (l/h) Vc (l) k12 (h1) k21 (h1) First pass extraction (%) Peff (104 cm/s)
Metoprolol 54a 84a 6.7a 2.4a 30a 1.3f
Diclofenac 16b 3.1b 4.4b 41b 60c 3.1g
Naproxen 21d 4.0d 0.093d 0.14d 0e 8.5f
Carbamazepine 1.1f 60.7f 0.036f 0.24f 1.25f 4.3f
API: active pharmaceutical ingredient; CL: clearance; First pass: ﬁrst passmetabolism; k12 and k21: distribution rate constants; Peff: human effective jejunal permeability;Vc:
volume of distribution.
a Sandberg et al. (1991).
b Rani et al. (2004).
c Peris-Ribera et al., (1991).
d Runkel et al. (1973).
e Yu and Amidon (1999).
f Sjögren et al. (2013).
g Tubic-Grozdanis et al. (2008).
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the goodness of ﬁt between the predicted and observed plasma
concentrations (Graham et al., 2012).
3. Results
3.1. Effect of diffusion barrier in the miniaturized release method
There was a correlation between the pore size of the diffusion
barrier and the time to reach equilibrium (time to reach plateau) in
the sample reservoir and the release medium (Fig. 2). The
equilibrium times for diclofenac across the nylon mesh ﬁlter, the
polyvinylideneﬂuorideﬁlterandcellulose-baseddialysismembrane
were 0.011h, 4.3h and 6.8h, respectively. For metoprolol, the
equilibrium times were 0.011h, 18h and 25h, respectively. The
correlation between equilibrium time, y (h), and pore size, x (mm)
was described as y =3.41.5 log x, R2 = 0.98, and y =135.4
log x,R2 = 0.96, fordiclofenac andmetoprolol, respectively. The time
to equilibrium for the nylonmeshﬁlter (with a pore size of 150mm)
was thusmore than a hundred times shorter than that for the other
twodiffusionbarriers: thepolyvinylideneﬂuorideﬁlter (withapore
size of 0.45mm)and the cellulose-based dialysismembrane (with a
pore size of 0.003mm).
The inﬂuence of stirring rate on theAPImass transport as amean
value of three observations,with thepolyvinylideneﬂuorideﬁlter as
diffusion barrier, is shown in Fig. 3. Themass transport of diclofenac
across the diffusion barrier was increasing with higher stirring rate.
However, therewas no correlation between the stirring rate and the
mass transport of metoprolol. After 1h of stirring at 100, 200 or
400 rpm, the mass transport of metoprolol across the diffusion
barrier was 76%, 86%, and 77%, respectively.
3.2. Indicated mechanisms of drug release
Interpretations of the b values in the Weibull function are
summarized in Table 3 (Papadopoulou et al., 2006). The drug
release proﬁles for each of the investigated DDSs are shown in
Fig. 4 and the corresponding a and b estimates are listed in Table 4.
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Fig. 2. (A) Transport of metoprolol and diclofenac in aqueous solution across three diffusion barriers. Metoprolol across the nylon mesh ﬁlter, 150mm pores, ( [TD$INLINE]); the
polyvinylidene ﬂuoride ﬁlter, 0.45mm pores, ( [TD$INLINE]); and the cellulose-based dialysis membrane, approximate pore size 0.003mm, ( [TD$INLINE]). Diclofenac across the nylon mesh
ﬁlter ( [TD$INLINE]); the polyvinylideneﬂuoride ﬁlter ( [TD$INLINE]), and the cellulose-based dialysismembrane ( [TD$INLINE]). All experimentswere carried out at 37 Cwith a stirring rate of 400 rpm.
(B) Correlation between equilibrium time (h) and pore size described with a nonlinear semi-log function for diclofenac and metoprolol, y =3.41.5 *log x,R2 = 0.98, and
y =135.4 *log x, R2 = 0.96, respectively.Metoprolol observed values ( [TD$INLINE]) and the non-linear semi-log function values ( [TD$INLINE]); diclofenac observed values ( [TD$INLINE]) and the non-linear
semi-log function values ( [TD$INLINE]).
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Fig. 3. (A) Effect of stirring rate on the transport of diclofenac in aqueous solution across the diffusion barrier. (B) Effect of stirring rate on the transport of metoprolol in
aqueous solution across the diffusion barrier. Both experiments were performed at 37 C with a polyvinylidene ﬂuoride ﬁlter (0.45mm pores) as diffusion barrier.
Table 3
Interpretations of estimated exponent b values in theWeibull function according
to Papadopoulou et al. (2006).
Indicated release mechanism
b<0.39 Not found in simulations. May occur in highly disordered
spaces that are very different from percolation clusters.
0.39<b<0.69 Diffusion in fractal or disordered substrates, different from
that in percolation clusters.
b0.690.75 Diffusion in normal Euclidian space.
0.75<b<1 Diffusion in normal Euclidian substrate with contribution
from another release mechanism.
b =1 First-order release.
b >1 Sigmoid curve indicative of a complex release mechanism.
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Fig. 4. In vitro drug release using data acquiredwith the novel, miniaturized,mDISSTM in vitro releasemethod and historical in vitro data. Symbols represent the observed data
and lines represent WinNonlin curve ﬁtting of the Weibull function. (A) Release proﬁle for metoprolol from a slurry of modiﬁed-release (MR) pellets using data from the
miniaturizedmethod and historical data (Gohel et al., 2009; Sandberg et al., 1988). (B) Release proﬁle formetoprolol from a slurry of immediate-release (IR) metoprolol using
miniaturized-method data and historical data (Löbenberg et al., 2005). (C) Release proﬁle for carbamazepine from a slurry of MR carbamazepine usingminiaturized-method
data and historical data (Friedman et al., 2000). (D) Release proﬁle for carbamazepine from a slurry of IR carbamazepine using miniaturized-method data and historical data
(Elqidra et al., 2004; Kovacevic et al., 2008; Nan et al., 2012). (E) Release proﬁle for carbamazepine froma carbamazepine oral suspension usingminiaturized-method data and
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The indicated types of drug release varied according to the
methodology used. Drug release through a highly disordered space
was indicated for one data set (IR carbamazepine) (Elqidra et al.,
2004). Drug release governed by diffusion in a fractal or disordered
substrate was indicated only by data for IR formulations, including
both the miniaturized-method experimental data for IR naproxen,
IR diclofenac and IR metoprolol and historical data for IR
carbamazepine and IR metoprolol (Kovacevic et al., 2008;
Löbenberg et al., 2005). Diffusion through a normal Euclidian
space was the most plausible drug release mechanism for one
historical set of MR carbamazepine data (Friedman et al., 2000).
Diffusion through a normal Euclidian space with the contribution
of another release mechanismwas suggested by historical data for
MR metoprolol (Gohel et al., 2009) and diclofenac gel (Gohel et al.,
2009; Parsaee et al., 2002), and by the miniaturized-method
experimental results for MR carbamazepine, the oral carbamaze-
pine suspension, and diclofenac gel. A ﬁrst-order release rate was
indicated by both historical data (Nan et al., 2012) and the
experimental results for IR carbamazepine. A sigmoidal release
curve, interpreted as indicating a complex releasemechanism, was
suggested by historical data sets for IR naproxen (Yuksel et al.,
2000), IR diclofenac (two data sets) (Al Ameri et al., 2012;
Nishihata, 1987) and MRmetoprolol Sandberg et al. (1988), as well
as by experimental data for MR metoprolol. The historical data for
the oral carbamazepine suspension had too few reported data
points (ﬁrst data point at 80% released) to be analyzed in this
manner.
3.3. In silico simulations of in vivo response
The simulations of the plasma proﬁles obtained with GI-Sim
were based on the miniaturized-method (mDISSTM) or historical in
vitro release proﬁles (Al Ameri et al., 2012; Elqidra et al., 2004;
Friedman et al., 2000; Gohel et al., 2009; Kovacevic et al., 2008;
Löbenberg et al., 2005; Nan et al., 2012; Nishihata, 1987; Parsaee
et al., 2002; Reiner et al., 2001; Sandberg et al., 1988; Yuksel et al.,
2000; Zhang et al., 2011; Zhou et al., 1998). The plasma-time
concentration proﬁles and the AUCs, maximum concentrations
(Cmax) and times to Cmax (tmax) from the experimental and
simulated data are shown in Fig. 5 and Table 5, respectively. The
agreement between the predicted concentration-time plasma
proﬁles and the observationswas assessed using the AAFEwith the
respective values at the times of the observations. In addition, the
predictive ability was evaluated from the agreement between the
observed and simulated PK parameters (AUC, tmax and Cmax). In
general, the simulations based on the data from theminiaturized in
vitro method were in good agreement with the observed plasma
proﬁles, with AAFE values in the range of 1.03–1.53. For ﬁve of the
seven investigated DDSs (71%), the in vivo predictions (i.e., the
accuracy of AUC, tmax and Cmax predictions) based on the
miniaturized-method experimental data were equally or more
accurate than the predictions based on historical in vitro release
data. For the remaining two DDSs, MR metoprolol and IR
carbamazepine, the in vivo prediction based on the miniatur-
ized-method experimental data was less accurate than that based
on two of the historical release data, with AAFE values of 1.53 and
1.31, respectively.
4. Discussion
Eight DDSs were investigated using a novel, miniaturized, in
vitro drug-release method and in silico modeling. The beneﬁts of
thismethod include the ability to collect data continuously, the use
of only small amounts of sample and release medium, and the
historical data (Zhang et al., 2011) (too few data points to perform curve ﬁtting). (F) Release proﬁle for diclofenac from diclofenac gel using miniaturized-method data and
historical data (Parsaee et al., 2002). (G) Release proﬁle for naproxen from a slurry of IR naproxen usingminiaturized-method data and historical data (Yuksel et al., 2000). (H)
Release proﬁle for diclofenac froma slurry of IR diclofenac usingminiaturized-method data and historical data (Al Ameri et al., 2012; Nishihata,1987). In vitro drug releasewas
measured with a 150mm nylon mesh ﬁlter as diffusion barrier and 10ml of PBS buffer, at a temperature of 37 C, with a stirring rate of 400 rpm.
Table 4
Estimation (CV%) of the Weibull function, using data obtained from the miniaturized experimental method (mDISSTM) or historical data.
API DDS a b AAFE Method Medium Reference
Naproxen IR IR 3 (2.8) 0.69 (2.4) 1.06 Miniaturized PBS pH 7.4
11 (2.9) 1.5 (1.2) 1.02 USP II PBS pH 7.4 Yuksel et al. (2000)
Metoprolol IR 3.5 (2.6) 0.5 (2.4) 1.02 Miniaturized PBS pH 7.4
4.6 (6.5) 0.48 (6.7) 1.01 USP II SGF Löbenberg et al. (2005)
Diclofenac IR 1.2 (1.2) 0.49 (2) 1.11 Miniaturized PBS pH 7.4
7.7 (5.9) 1.8 (2.6) 1.03 USP II 0.1N HCl Al Ameri et al. (2012)
0.53 (6.1) 1.3 (6.5) 1.04 Shaken beaker PBS pH 6.8 Nishihata (1987)
Carbamazepine IR 0.39 (1.8) 1 (1.4) 1.00 Miniaturized PBS pH 7.4
1.3 (1.7) 0.27 (4.9) 1.01 USP II 1% SLS Elqidra et al. (2004)
1 (4.1) 1 (6.2) 1.06 Basket 0.1mol/L HCl Nan et al. (2012)
0.55 (1.4) 0.4 (5.3) 1.04 USP II PBS pH 6.8 Kovacevic et al. (2008)
Carbamazepine MR 0.13 (1.3) 0.9 (0.6) 1.02 Miniaturized PBS pH 7.4
0.74 (5) 0.72 (7.3) 1.95 USP II 1% SLS Friedman et al. (2000)
Metoprolol MR 0.039 (4.4) 1.3 (1.3) 1.06 Miniaturized PBS pH 7.4
0.12 (14) 0.91 (7.4) 1.07 USP II PBS pH 6.8 Gohel et al. (2009)
0.046 (7.5) 1.2 (2.5) 1.07 USP II PBS pH 6.8 Sandberg et al. (1988)
Carbamazepine Susp 9.6 (6.1) 0.87 (2.8) 1.03 Miniaturized PBS pH 7.4
NA* NA* NA* USP II Water Zhang et al. (2011)
Diclofenac Gel 1.1 (2.1) 0.89 (2.9) 1.15 Miniaturized PBS pH 7.4
0.056 (3.6) 0.9 (4.4) 1.05 Franz cell PBS pH 7.4 Parsaee et al. (2002)
AAFE: absolute average fold error; a and b: constants in the Weibull function estimated with WinNonlin; API: active pharmaceutical ingredient; CV: coefﬁcient of variation;
DDS: drug delivery system; Gel: dermal gel; IR: immediate-release tablet; MR: modiﬁed-release tablet; NA*: not available because of too few data points; PBS: phosphate
buffered saline; SGF: simulated gastric ﬂuid without enzymes; SLS: sodium lauryl sulfate; Susp: oral suspension; USP: United States Pharmacopeia.
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Fig. 5. Historical in vivo drug concentrations in plasma over time (CP OBS) and simulated (GI-Sim) in vivo plasma concentration-time proﬁles based on in vitro data obtained
from the miniaturized method (mDISSTM) (data acquired with a nylon mesh, pore size 150mm) and historical sources. Symbols represent historical CP OBS, lines represent
simulated plasma concentrations. (A) observed data from Sandberg et al. (1988), simulated red line data from Gohel et al. (2009), simulated green line data from Sandberg
et al. (1988), and simulated blue line data from theminiaturizedmethod. (B) observed data fromSandberg et al. (1988), red line data fromLöbenberg et al. (2005) and blue line
data from theminiaturizedmethod. (C) observed data fromZhang et al. (2011), red line data from Friedman et al. (2000), and blue line data from theminiaturizedmethod. (D)
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possibility of modifying the method by changing the diffusion
barrier. The in vitro release proﬁles obtained using the miniatur-
ized mDISSTM system were suitable for release mechanism
analysis, and the predictability of in vivo behavior from the
miniaturized-method data, evaluated using the biopharmaceutical
in silico model GI-Sim (Sjögren et al., 2013) was generally more
accurate than that from the historical data.
4.1. Evaluation of the diffusion barrier
The diffusion barrier investigation showed that the nylon mesh
ﬁlter with 150mm pores had only a minor impact on the
equilibrium time (0.011h), while the ﬁlters with smaller pores
signiﬁcantly increased the equilibrium time. There are several
possible explanations for this observation. The pore size in the
nylonmesh ﬁlter was presumably sufﬁciently large to facilitate the
ﬂow of ﬂuids. Since the smaller pores reduced this fast ﬂuid ﬂow,
the dominating mass transport mechanism across the dialysis
membrane and the polyvinylidene ﬁlter may thus have been the
slower molecular diffusion (Kostewicz et al., 2014b). The total
available pore area determines the rate of mass transport when
molecular diffusion is the main mechanism of transport. The two
selected APIs, diclofenac andmetoprolol, showed slightly different
equilibrium times for the dialysis membrane which might be
explained by different API afﬁnity to the same dialysis membrane.
Possibly, the positively charged metoprolol (pKa = 9.7) is attracted
to the negatively charged cellulosemembranewhile the negatively
charged diclofenac is not (pKa = 3.8). In all, care should be taken
when choosing an appropriate diffusion barrier since the material
may affect the equilibrium time. However, for DDSs such as
emulsions, a dialysis membrane could prevent the formulation
from spreading outside the sample reservoir, thereby reducing the
pharmaceutical effect of the excipients on theUVmeasurements as
well as better control of the available total surface area for release
(Morais and Burgess, 2014). If the diffusion barrier inﬂuences the
API mass transport, this effect needs to be evaluated and corrected
for in future data analyses (Levy and Benita, 1990; Washington,
1989).
A stirring rate of 400 rpm allowed sufﬁciently fast mass
transport across the nylon mesh to minimize any inﬂuence on
the drug-release proﬁles. However, further hydrodynamic investi-
gation of the inﬂuence of the stirring rate on mass transport in the
miniaturized release method is needed and is currently on-going.
4.2. Interpretation of the in vitro drug-release mechanism from drug
delivery systems
The use of the Weibull function, suggested by Papadopoulou
et al. (2006) facilitates straightforward analysis of drug-release
mechanisms and is applicable for awide range of formulations and
types ofmechanism. The release of the drug in fractal or disordered
matrices appears to be driven only by diffusion. Diffusion in
irregular fractal spaces is slower than in a homogeneous Euclidian
space (Kosmidis et al., 2003a). Diffusion in a homogeneous space
observed data fromKovacevic et al. (2008), red line data fromElqidra et al. (2004), green line data fromKovacevic et al. (2008), purple line data fromNan et al. (2012), and blue
line data from theminiaturizedmethod. (E) observed data fromZhang et al. (2011), red line data fromZhang et al. (2011), and blue line data from theminiaturizedmethod. (F)
observed data fromZhou et al. (1998), red line data fromYuksel et al. (2000), and blue line data from theminiaturizedmethod. (G) observed data fromReiner et al. (2001), red
line data from Al Ameri et al. (2012), green line data from Nishihata et al. (1987), and blue line data from the miniaturized method. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 5
Pharmacokinetic parameters (AUC, Cmax, tmax) from clinical observations (in bold) and in vitro-based in silico simulations (in italics).
API DDS AUC (ng*h/ml) tmax (h) Cmax (ng/ml) AAFE Reference
Naproxen IR 1200000 3 68000 Zhou et al. (1998)
1300000 1.1 110000 1.26 Miniaturized method
1300000 0.96 110000 1.27 Yuksel et al. (2000)
Metoprolol IR 1300 1 170 Sandberg et al. (1988)
1300 1.9 160 1.11 Miniaturized method
1200 1.9 160 1.12 Löbenberg et al. (2005)
Diclofenac IR 1100 0.5 980 Reiner et al. (2001)
1200 0.48 710 1.42 Miniaturized method
1200 0.64 1200 1.73 Al Ameri et al. (2012)
1200 0.96 410 1.83 Nishihata (1987)
Carbamazepine IR 150000 6.5 3800 Kovacevic et al. (2008)
180000 8.2 5000 1.31 Miniaturized method
170000 1.9 4700 1.39 Elqidra et al. (2004)
190000 4 5500 1.52 Nan et al. (2012))
140000 9.6 3700 1.12 Kovacevic et al. (2008)
Carbamazepine MR 120000 24 3000 Zhang et al. (2011)
130000 16 3400 1.24 Miniaturized method
180000 6.9 4900 1.87 Friedman et al. (2000)
Metoprolol MR 820 6 40 Sandberg et al. (1988)
800 12 47 1.53 Miniaturized method
820 8.2 47 1.30 Gohel et al. (2009)
750 12 43 1.70 Sandberg et al. (1988)
Carbamazepine Susp 31000 0.99 3100 Zhang et al. (2011)
31000 1.4 3100 1.03 Miniaturized method
33000 1.6 3200 1.08 Zhang et al. (2011)
AAFE: absolute average fold error; API: active pharmaceutical ingredient; AUC: area under the concentration-time curve; Cmax: maximum concentration; DDS: drug delivery
system; IR: immediate-release tablet; MR: modiﬁed-release tablet; Susp: oral suspension; tmax: time to Cmax.
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when another release mechanism also is involved indicates
diffusion-driven release with additional input from case II
transport. In case II transport, the relaxation of the tablet matrix
polymers inﬂuences the movement of the APIs through the matrix
(Kosmidis et al., 2003c). First-order drug release follows Fick’s law
of diffusion (Papadopoulou et al., 2006). A sigmoidal release curve
is indicative of a complex release mechanism, involving erosion-
based release or the release of a relatively insoluble API (Kosmidis
et al., 2003b; Papadopoulou et al., 2006).
The drug-release mechanisms for seven of the IR formulation
data sets (see Table 4) were, in accordance with theory and
formulation strategy, based on diffusion through a fractal/
disordered matrix or diffusion according to Fick’s law (ﬁrst-order
release). In contrast, the data sets for IR naproxen and IR diclofenac
suggested complex release mechanisms involving erosion or
inﬂuence of the relative insolubility of the APIs (Kosmidis et al.,
2003b).
The release kinetics for the individually coated pellets of MR
metoprolol indicated almost zero-order release over 24h (Sand-
berg et al.,1988). To provide a drug releasemechanism that follows
zero-order kinetics, the DDS must be designed to overcome Fick’s
law of diffusion, in which the diffusion is non-linear over time due
to the changes in surface area and diffusion length (Chidambaram
et al., 1998). Therefore, a more complex mechanism is required;
this can be achieved, for example, by coating the pellets, as seen
with the ethylcellulose coating used in MR metoprolol (Sandberg
et al., 1988; Varelas et al., 1995). For the three MR metoprolol data
sets, the indicated release mechanisms were either a complex
mechanism or diffusion-controlled in combination with case II
transport. Hence, the indicated release mechanisms for MR
metoprolol are in line with the reported approximate zero-order
release (Sandberg et al., 1988).
ForMR carbamazepine, the releasemechanism indicated by the
miniaturized-method datawas different from that indicated by the
historical data (see Table 4) (Friedman et al., 2000). API releasewas
driven only by diffusion in the historical data set, while the
miniaturized-method data set indicated the presence of diffusion
with contribution from case II transport.WhenMR carbamazepine
is used clinically, the patient is instructed not to crush the tablets.
However, the prolonged in vitro release from the crushed tablet
indicated that the individually coated pellets of the MR tablet
remained intact (Kesarwani et al., 2007).
The difference in the rate of drug release from diclofenac gel
between data obtained using the miniaturized method and
historical data was probably due to the large difference in pore
size (more than a 50,000-fold difference) between the diffusion
barriers. Nylonmesh (150mmpores) was used in the miniaturized
method, whereas a cellulose acetate dialysis membrane with a
molecular weight cut-off point of 1000 was used for collection of
the historical data (Parsaee et al., 2002).
In the novel, miniaturized, mDISSTM in vitro method, only a
representative proportion of each DDS was investigated whereas,
in the historical release methods, an intact formulation unit such
as a tablet was examined. While the surface area of the diffusion
barrier was constant during the miniaturized-method experi-
ments, the surface area of the particles was not constant. The
historical in vitro release experiments differed in the applied
release equipment and set-ups, such as stirring rate, release
medium (e.g., differing in pH and/or the addition of surfactant), as
well as in the volume of release medium used (Al Ameri et al.,
2012; Elqidra et al., 2004; Friedman et al., 2000; Gohel et al., 2009;
Kovacevic et al., 2008; Löbenberg et al., 2005; Nan et al., 2012;
Nishihata, 1987; Parsaee et al., 2002; Sandberg et al., 1988; Yuksel
et al., 2000; Zhang et al., 2011). Therefore, the in vitro release proﬁle
and consequently the indicated release mechanism varied for the
investigated DDS. As an example, the four in vitro data sets for IR
carbamazepine differed with regard to the release method and the
release medium used, and consequently the b values ranged
between 0.27 and 1.0. The DDS for IR metoprolol was the
exception; the same release mechanism was indicated in both
the miniaturized-method and historical data sets. As expected, the
release mechanism differed between the IR, MR and non-solid
drug delivery systems. In conclusion, there was wide variation in
the indicated release mechanisms between the data sets. The
differences in method set-ups seemed to affect the drug release to
a greater extent than the differences caused by using a
representative part of the DDS or an intact unit.
4.3. Gastrointestinal (GI) absorption simulation
In vitro data originating from both the miniaturized method
and the historical investigations for four model drugs were
inserted into the in silico model GI-Sim to predict the plasma
concentration-time proﬁles in vivo. The in vitro release proﬁles as
well as selected parameters listed in Tables 1 and 2 determined the
predicted in vivo response. As shown in Fig. 4 the in vitro release
method had an impact on the release proﬁles and consequently on
the predicted plasma-time proﬁles. Based on the in vitro drug-
release proﬁles, GI drug absorption was predicted to occur mainly
from the proximal small intestine or throughout the whole
intestine including the colon. The potential for colonic absorption
will be relevant for DDSs with prolonged drug-release proﬁles
(>3h), such as MR metoprolol, MR carbamazepine, and IR
carbamazepine, as the speciﬁed mean transit time to reach the
colon in GI-Sim is 3.5 h (Sjögren et al., 2013). Overall, the
experimental data acquired with the novel, miniaturized, in vitro
mDISSTM method gave more accurate predictions of the plasma
concentration proﬁles than the historical in vitro data. The
predictions based on the miniaturized method data were equally
or more accurate than the predictions based on historical in vitro
release data for 71% of the investigated DDSs. This was the case for
both IR andMR formulations, indicating the overall accuracy of the
modiﬁed miniaturized method. However, for IR carbamazepine
and MR metoprolol one historical in vitro release data set for each
formulation gave more accurate predictions. The in vivo proﬁle for
MR carbamazepine was very well described by the in vitro data,
while the in vitro data for IR carbamazepine were somewhat less
predictive. This appears contradictory, as it could be assumed that
the in vitro drug-release proﬁle for an IR formulation would be
more likely to reﬂect the in vivo release proﬁle. The inaccurate
prediction for the IR formulation was also observed for two
historical data sets (Elqidra et al., 2004; Nan et al., 2012). The in
vivo predictions based on the in vitro data set from Kovacevic et al.
were, however, accurate (Kovacevic et al., 2008). It is noteworthy
that, in this investigation of the IR formulation, only 50% of the
carbamazepine was released in 2h (Kovacevic et al., 2008). The
administered dose was predicted to be incompletely absorbed
throughout the small and large intestine as a consequence of this
slow release. For MR metoprolol, the in vitro release of the three
data sets are quite similar (see Fig. 4), however, the predicted
plasma-time proﬁles (see Fig. 5) are not. One in vitro release data
set (Gohel et al., 2009) have a slightly higher drug release
compared to the miniaturized method which lead to a higher
absorption of metoprolol before the colon compartment of GI-Sim.
This might be explained by a delay in the predicted tmax when
based on release data from the miniaturized method.
In this study, the combination of in vitro and in silico tools was a
valuable asset for the evaluation of the in vivo predictive
performance of the in vitro results. This advantageous combination
has been shown previously, and there is an ongoing effort to
further improve these synergistic methodologies (Kostewicz et al.,
2014a; Lennernäs et al., 2014b).
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5. Conclusion
The developed in vitro release method based on the miniatur-
ized mDISSTM technique enables continuous sampling with small
volumes of both DDS (21ml) and release medium (10ml). In this
experimental study, in vitro release data were collected from eight
selected DDSs with four APIs. Collection of API release data was
possible for both solid and non-solid formulations, as well as for
charged and uncharged APIs. Both the miniaturized-method and
the historical release data were used to estimate the release
mechanisms and to predict the plasma concentration-time proﬁles
in a biopharmaceutical GI absorption model (Al Ameri et al., 2012;
Elqidra et al., 2004; Friedman et al., 2000; Gohel et al., 2009;
Kovacevic et al., 2008; Löbenberg et al., 2005; Nan et al., 2012;
Nishihata, 1987; Parsaee et al., 2002; Reiner et al., 2001; Sandberg
et al., 1988; Sjögren et al., 2013; Yuksel et al., 2000; Zhang et al.,
2011; Zhou et al., 1998). The indicated release mechanisms for the
APIs varied according to the source of the data. This discrepancy
most likely originated from differences in the methods used, such
as the stirring rate, the release medium used, and the in vitro
apparatus used. For ﬁve of the seven evaluable drug formulations,
predictions of the in vivo plasma concentration-time proﬁles
obtained using the novel, miniaturized,mDISSTM in vitro data were
at least as accurate as those obtained from the historical in vitro
data. These promising results could reduce the amounts of the
formulations and releasemedia required in the collection of in vitro
data, while still generating accurate in vivo predictions.
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